
Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through skp2-mediated proteasomal degradation of tpl2
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:

ABSTRACT While mechanisms for metastasis were extensively studied in cancer cells from patients with detectable tumors, pathways underlying metastatic dissemination from early lesions before
primary tumors appear are poorly understood. Her2 promotes breast cancer early dissemination by suppressing p38, but how Her2 downregulates p38 is unclear. Here, we demonstrate that in
early lesion breast cancer models, Her2 inhibits p38 by inducing Skp2 through Akt-mediated phosphorylation, which promotes ubiquitination and proteasomal degradation of Tpl2, a p38 MAP3K.
The early disseminating cells are Her2+Skp2highTpl2lowp-p38lowE-cadherinlow in the MMTV-Her2 breast cancer model. In human breast carcinoma, high Skp2 and low Tpl2 expression are associated
with the Her2+ status; Tpl2 expression positively correlates with that of activated p38; Skp2 expression negatively correlates with that of Tpl2 and activated p38. Moreover, the
Her2-Akt-Skp2-Tpl2-p38 axis plays a key role in the disseminating phenotypes in early lesion breast cancer cells; inhibition of Tpl2 enhances early dissemination in vivo. These findings
identify the Her2-Akt-Skp2-Tpl2-p38 cascade as a novel mechanism mediating breast cancer early dissemination and a potential target for novel therapies targeting early metastatic
dissemination. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution
Subscribe to this journal Receive 50 print issues and online access $259.00 per year only $5.18 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full
article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs *
Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS HER2 PROMOTES EARLY DISSEMINATION OF BREAST CANCER BY SUPPRESSING THE P38-MK2-HSP27 PATHWAY THAT IS TARGETABLE BY WIP1
INHIBITION Article 26 August 2020 THE EXTRACELLULAR-REGULATED PROTEIN KINASE 5 (ERK5) ENHANCES METASTATIC BURDEN IN TRIPLE-NEGATIVE BREAST CANCER THROUGH FOCAL ADHESION PROTEIN KINASE
(FAK)-MEDIATED REGULATION OF CELL ADHESION Article Open access 12 May 2021 PAK5 PROMOTES THE TRASTUZUMAB RESISTANCE BY INCREASING HER2 NUCLEAR ACCUMULATION IN HER2-POSITIVE BREAST CANCER
Article Open access 21 April 2025 CHANGE HISTORY * _ 11 FEBRUARY 2021 A Correction to this paper has been published: https://doi.org/10.1038/s41388-021-01652-5 _ REFERENCES * Fidler IJ. The
pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3:453–8. Article CAS PubMed Google Scholar * Narod SA, Iqbal J, Giannakeas V, Sopik V,
Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 2015;1:888–96. Article PubMed Google Scholar * Pantel K, Brakenhoff RH. Dissecting the metastatic
cascade. Nat Rev Cancer. 2004;4:448–56. Article CAS PubMed Google Scholar * Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history
and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994;12:1272–80. Article CAS PubMed Google Scholar * Riethmuller G, Klein CA. Early cancer cell dissemination and late
metastatic relapse: clinical reflections and biological approaches to the dormancy problem in patients. Semin Cancer Biol. 2001;11:307–11. Article CAS PubMed Google Scholar *
Lopez-Lazaro M. The migration ability of stem cells can explain the existence of cancer of unknown primary site. Rethinking metastasis. Oncoscience. 2015;2:467–75. Article PubMed PubMed
Central Google Scholar * Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of
melanoma. J Clin Invest. 2010;120:2030–9. Article CAS PubMed PubMed Central Google Scholar * Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models
and cancer patients. Cancer Cell. 2013;23:573–81. Article CAS PubMed PubMed Central Google Scholar * Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in
development and disease. Cell. 2009;139:871–90. Article CAS PubMed Google Scholar * Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression
by epithelial tumor cells reveals an invasion suppressor role. Cell. 1991;66:107–19. Article CAS PubMed Google Scholar * Aberle H, Schwartz H, Kemler R. Cadherin-catenin complex: protein
interactions and their implications for cadherin function. J Cell Biochem. 1996;61:514–23. Article CAS PubMed Google Scholar * Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F,
Mareel MM, et al. Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a
temperature-sensitive v-SRC gene. J Cell Biol. 1993;120:757–66. Article CAS PubMed Google Scholar * Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science.
2004;303:1483–7. Article CAS PubMed PubMed Central Google Scholar * Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the
MAP kinase kinases MKK3 and MKK6. J Biol Chem. 1998;273:1741–8. Article CAS PubMed Google Scholar * Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J.
2010;429:403–17. Article CAS PubMed Google Scholar * Shi Y, Gaestel M. In the cellular garden of forking paths: how p38 MAPKs signal for downstream assistance. Biol Chem.
2002;383:1519–36. Article CAS PubMed Google Scholar * Gantke T, Sriskantharajah S, Sadowski M, Ley SC. IkappaB kinase regulation of the TPL-2/ERK MAPK pathway. Immunol Rev.
2012;246:168–82. Article PubMed Google Scholar * Salmeron A, Ahmad TB, Carlile GW, Pappin D, Narsimhan RP, Ley SC. Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP
kinase kinase kinase. EMBO J. 1996;15:817–26. Article CAS PubMed PubMed Central Google Scholar * Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin JH, et al. TNF-alpha
induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell. 2000;103:1071–83. Article CAS PubMed Google Scholar * Pattison MJ, Mitchell O, Flynn HR, Chen
CS, Yang HT, Ben-Addi H, et al. TLR and TNF-R1 activation of the MKK3/MKK6-p38alpha axis in macrophages is mediated by TPL-2 kinase. Biochem J. 2016;473:2845–61. Article CAS PubMed
Google Scholar * Senger K, Pham VC, Varfolomeev E, Hackney JA, Corzo CA, Collier J, et al. The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation. Sci Signal.
2017;10. * Gong J, Fang C, Zhang P, Wang PX, Qiu Y, Shen LJ, et al. Tumor progression locus 2 in hepatocytes potentiates both liver and systemic metabolic disorders in mice. Hepatology.
2019;69:524–44. Article CAS PubMed Google Scholar * Beinke S, Robinson MJ, Hugunin M, Ley SC. Lipopolysaccharide activation of the TPL-2/MEK/extracellular signal-regulated kinase
mitogen-activated protein kinase cascade is regulated by IkappaB kinase-induced proteolysis of NF-kappaB1 p105. Mol Cell Biol. 2004;24:9658–67. Article CAS PubMed PubMed Central Google
Scholar * Dodhiawala PB, Khurana N, Zhang D, Cheng Y, Li L, Wei Q, et al. TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations. J Clin Invest.
2020;130:4771–90. Article CAS PubMed PubMed Central Google Scholar * Cho J, Melnick M, Solidakis GP, Tsichlis PN. Tpl2 (tumor progression locus 2) phosphorylation at Thr290 is induced
by lipopolysaccharide via an Ikappa-B Kinase-beta-dependent pathway and is required for Tpl2 activation by external signals. J Biol Chem. 2005;280:20442–8. Article CAS PubMed Google
Scholar * Bulavin DV, Fornace AJ Jr. p38 MAP kinase’s emerging role as a tumor suppressor. Adv Cancer Res. 2004;92:95–118. Article CAS PubMed Google Scholar * Zheng H, Seit-Nebi A, Han
X, Aslanian A, Tat J, Liao R, et al. A posttranslational modification cascade involving p38, Tip60, and PRAK mediates oncogene-induced senescence. Mol Cell. 2013;50:699–710. Article CAS
PubMed PubMed Central Google Scholar * Ellinger-Ziegelbauer H, Kelly K, Siebenlist U. Cell cycle arrest and reversion of Ras-induced transformation by a conditionally activated form of
mitogen-activated protein kinase kinase kinase 3. Mol Cell Biol. 1999;19:3857–68. Article CAS PubMed PubMed Central Google Scholar * She QB, Bode AM, Ma WY, Chen NY, Dong Z.
Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res. 2001;61:1604–10. CAS PubMed Google Scholar *
Wen HC, Avivar-Valderas A, Sosa MS, Girnius N, Farias EF, Davis RJ, et al. p38alpha signaling induces anoikis and lumen formation during mammary morphogenesis. Sci Signal. 2011;4:ra34.
Article PubMed PubMed Central Google Scholar * Huang S, New L, Pan Z, Han J, Nemerow GR. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix
invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity. J Biol Chem. 2000;275:12266–72. Article CAS PubMed Google Scholar * Anwar T,
Arellano-Garcia C, Ropa J, Chen YC, Kim HS, Yoon E, et al. p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis. Nat Commun.
2018;9:2801. Article PubMed PubMed Central Google Scholar * Wu MZ, Chen SF, Nieh S, Benner C, Ger LP, Jan CI, et al. Hypoxia drives breast tumor malignancy through a
TET-TNFalpha-p38-MAPK signaling axis. Cancer Res. 2015;75:3912–24. Article CAS PubMed Google Scholar * Harper KL, Sosa MS, Entenberg D, Hosseini H, Cheung JF, Nobre R, et al. Mechanism
of early dissemination and metastasis in Her2(+) mammary cancer. Nature. 2016;540:588–92. Article CAS PubMed PubMed Central Google Scholar * Kim G, Khanal P, Kim JY, Yun HJ, Lim SC,
Shim JH, et al. COT phosphorylates prolyl-isomerase Pin1 to promote tumorigenesis in breast cancer. Mol Carcinog. 2015;54:440–8. Article CAS PubMed Google Scholar * Kim K, Kim G, Kim JY,
Yun HJ, Lim SC, Choi HS. Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation. Carcinogenesis. 2014;35:1352–61. Article CAS PubMed Google
Scholar * Decicco-Skinner KL, Trovato EL, Simmons JK, Lepage PK, Wiest JS. Loss of tumor progression locus 2 (tpl2) enhances tumorigenesis and inflammation in two-stage skin
carcinogenesis. Oncogene. 2011;30:389–97. Article CAS PubMed Google Scholar * Gkirtzimanaki K, Gkouskou KK, Oleksiewicz U, Nikolaidis G, Vyrla D, Liontos M, et al. TPL2 kinase is a
suppressor of lung carcinogenesis. Proc Natl Acad Sci USA. 2013;110:E1470–1479. Article CAS PubMed PubMed Central Google Scholar * Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge
JS. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol. 2001;3:785–92. Article CAS PubMed PubMed Central Google Scholar
* Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. Cancer Cell. 2008;13:58–68. Article PubMed Google Scholar *
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15. Article CAS PubMed
PubMed Central Google Scholar * Xu L, Chen S, Bergan RC. MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell
invasion in human prostate cancer. Oncogene. 2006;25:2987–98. Article CAS PubMed Google Scholar * Han Y, Zhang L, Wang W, Li J, Song M. Livin promotes the progression and metastasis of
breast cancer through the regulation of epithelialmesenchymal transition via the p38/GSK3beta pathway. Oncol Rep. 2017;38:3574–82. CAS PubMed Google Scholar * Yan MH, Hao JH, Zhang XG,
Shen CC, Zhang DJ, Zhang KS, et al. Advancement in TPL2-regulated innate immune response. Immunobiology. 2019;224:383–7. Article CAS PubMed Google Scholar * Slack DN, Seternes OM,
Gabrielsen M, Keyse SM. Distinct binding determinants for ERK2/p38alpha and JNK map kinases mediate catalytic activation and substrate selectivity of map kinase phosphatase-1. J Biol Chem.
2001;276:16491–500. Article CAS PubMed Google Scholar * Candas D, Lu CL, Fan M, Chuang FY, Sweeney C, Borowsky AD, et al. Mitochondrial MKP1 is a target for therapy-resistant
HER2-positive breast cancer cells. Cancer Res. 2014;74:7498–509. Article CAS PubMed PubMed Central Google Scholar * Mamillapalli R, Gavrilova N, Mihaylova VT, Tsvetkov LM, Wu H, Zhang
H, et al. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr Biol. 2001;11:263–7. Article CAS PubMed Google
Scholar * Gao D, Inuzuka H, Tseng A, Chin RY, Toker A, Wei W. Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol.
2009;11:397–408. Article CAS PubMed PubMed Central Google Scholar * Lin HK, Wang G, Chen Z, Teruya-Feldstein J, Liu Y, Chan CH, et al. Phosphorylation-dependent regulation of cytosolic
localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol. 2009;11:420–32. Article CAS PubMed PubMed Central Google Scholar * Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng
Z, et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 2012;149:1098–111. Article CAS PubMed PubMed Central Google
Scholar * Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N, Moasser MM. HER2 amplification in tumors activates PI3K/Akt signaling independent of HER3. Cancer Res. 2018;78:3645–58.
Article CAS PubMed PubMed Central Google Scholar * Wisinski KB, Tevaarwerk AJ, Burkard ME, Rampurwala M, Eickhoff J, Bell MC, et al. Phase I study of an AKT Inhibitor (MK-2206) combined
with lapatinib in adult solid tumors followed by dose expansion in advanced HER2+ breast cancer. Clin Cancer Res. 2016;22:2659–67. Article CAS PubMed PubMed Central Google Scholar *
Krcova Z, Ehrmann J, Krejci V, Eliopoulos A, Kolar Z. Tpl-2/Cot and COX-2 in breast cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152:21–25. Article PubMed Google
Scholar * del Barco Barrantes I, Nebreda AR. Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans. 2012;40:79–84. Article PubMed Google Scholar * Sosa MS, Avivar-Valderas A,
Bragado P, Wen HC, Aguirre-Ghiso JA. ERK1/2 and p38alpha/beta signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin Cancer Res. 2011;17:5850–7. Article
CAS PubMed PubMed Central Google Scholar * Chan CH, Lee SW, Wang J, Lin HK. Regulation of Skp2 expression and activity and its role in cancer progression. ScientificWorldJournal.
2010;10:1001–15. Article CAS PubMed PubMed Central Google Scholar * Weidensdorfer D, Stohr N, Baude A, Lederer M, Kohn M, Schierhorn A, et al. Control of c-myc mRNA stability by
IGF2BP1-associated cytoplasmic RNPs. RNA. 2009;15:104–15. Article CAS PubMed PubMed Central Google Scholar * Kato H, Asamitsu K, Sun W, Kitajima S, Yoshizawa-Sugata N, Okamoto T, et al.
Cancer-derived UTX TPR mutations G137V and D336G impair interaction with MLL3/4 complexes and affect UTX subcellular localization. Oncogene. 2020;39:3322–35. Article CAS PubMed Google
Scholar * Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, et al. Single-cell phosphoproteomics resolves adaptive signaling dynamics and informs targeted combination therapy in
glioblastoma. Cancer Cell. 2016;29:563–73. Article CAS PubMed PubMed Central Google Scholar Download references ACKNOWLEDGEMENTS We thank Cell Engineering and Tumor Tissue and Pathology
Shared Resources of WFBCCC for support. This study was supported by NIH/NCI grants CA131231, CA172115, and P30CA012197 (PS) and Bilateral Inter-Governmental S&T Cooperation Project
grants from Ministry of Science and Technology of China (81972882 and 2018YFE0114300) (RX). PS is an Anderson Oncology Research Professor. AUTHOR INFORMATION Author notes * These authors
contributed equally: Guanwen Wang, Juan Wang AUTHORS AND AFFILIATIONS * Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston-Salem, NC,
USA Guanwen Wang, Juan Wang, Antao Chang, Dongmei Cheng, Shan Huang, Dan Wu, Sherona Sirkisoon, Hui-Kuan Lin, Hui-Wen Lo & Peiqing Sun * Department of Immunology, School of Medicine,
Nankai University, Tianjin, China Guanwen Wang, Juan Wang, Antao Chang, Shan Huang, Shuang Yang & Rong Xiang Authors * Guanwen Wang View author publications You can also search for this
author inPubMed Google Scholar * Juan Wang View author publications You can also search for this author inPubMed Google Scholar * Antao Chang View author publications You can also search for
this author inPubMed Google Scholar * Dongmei Cheng View author publications You can also search for this author inPubMed Google Scholar * Shan Huang View author publications You can also
search for this author inPubMed Google Scholar * Dan Wu View author publications You can also search for this author inPubMed Google Scholar * Sherona Sirkisoon View author publications You
can also search for this author inPubMed Google Scholar * Shuang Yang View author publications You can also search for this author inPubMed Google Scholar * Hui-Kuan Lin View author
publications You can also search for this author inPubMed Google Scholar * Hui-Wen Lo View author publications You can also search for this author inPubMed Google Scholar * Rong Xiang View
author publications You can also search for this author inPubMed Google Scholar * Peiqing Sun View author publications You can also search for this author inPubMed Google Scholar
CONTRIBUTIONS GW, JW, RX, and PS conceived and designed the study. GW, JW, MD, SH, AC, and DW executed the experiments; GW, JW, AC, KL, SS, HL, HL, and PS analyzed and interpreted the data.
GW, JW, HL, HL, RX, and PS wrote and/or reviewed the manuscript. CORRESPONDING AUTHORS Correspondence to Rong Xiang or Peiqing Sun. ETHICS DECLARATIONS CONFLICT OF INTEREST The authors
declare that they have no conflict of interest. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations. SUPPLEMENTARY INFORMATION SUPPLEMENTAL INFORMATION RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Wang, G., Wang, J., Chang,
A. _et al._ Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through Skp2-mediated proteasomal degradation of Tpl2. _Oncogene_ 39, 7034–7050 (2020).
https://doi.org/10.1038/s41388-020-01481-y Download citation * Received: 26 February 2020 * Revised: 21 August 2020 * Accepted: 17 September 2020 * Published: 28 September 2020 * Issue Date:
19 November 2020 * DOI: https://doi.org/10.1038/s41388-020-01481-y SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a
shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative